Armed with positive data from a phase 2b trial, Teva and Sanofi have decided to push their anti-TL1A antibody duvakitug into a phase 3 programme in inflammatory bowel disease (IBD). The results of ...

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

After hours: January 31 at 7:58:37 p.m. EST ...

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world ...